N-Carbamoylaspartic acid

Identification

Summary

N-Carbamoylaspartic acid is an amino acid commonly found as a component in total parenteral nutrition.

Generic Name
N-Carbamoylaspartic acid
DrugBank Accession Number
DB04252
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 176.1274
Monoisotopic: 176.043321376
Chemical Formula
C5H8N2O5
Synonyms
  • 2-Ureidobutanedioic acid
  • L-N-Carbamoylaspartic acid
  • N-Carbamoyl-S-aspartic acid
  • N-Carbamoylaspartic acid
  • Ureidosuccinic acid
External IDs
  • NSC-14983

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UDihydroorotaseNot AvailableEscherichia coli (strain K12)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Pyrimidine MetabolismMetabolic
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)Disease
Aspartate MetabolismMetabolic
beta-Ureidopropionase DeficiencyDisease
Canavan DiseaseDisease
Dihydropyrimidinase DeficiencyDisease
HypoacetylaspartiaDisease
UMP Synthase Deficiency (Orotic Aciduria)Disease
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DEKAMINN-Carbamoylaspartic acid (3.14 g/L) + Alanine (4.4 g/L) + Arginine (7.2 g/L) + Glutamic acid (5.18 g/L) + Glycine (12.8 g/1L) + Histidine (3.2 g/L) + Isoleucine (3.7 g/L) + Leucine (5.9 g/l) + Lysine (4.24 g/L) + Methionine (5.9 g/L) + Phenylalanine (5.9 g/L) + Proline (4.14 g/L) + Pyridoxine (0.05 g/L) + Serine (5.6 g/L) + Threonine (2.64 g/L) + Tryptophan (1.32 g/L) + Tyrosine (0.5 g/L) + Valine (4.24 g/L)Injection, solutionIntravenousMonico S.P.A.2014-07-08Not applicableItaly flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Aspartic acid and derivatives
Alternative Parents
Fatty acids and conjugates / Dicarboxylic acids and derivatives / Isoureas / Carboxylic acids / Carboximidamides / Organopnictogen compounds / Organic oxides / Imines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Aspartic acid or derivatives / Carbonyl group / Carboximidamide / Carboximidic acid derivative / Carboxylic acid / Dicarboxylic acid or derivatives / Fatty acid / Hydrocarbon derivative / Imine
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
L-aspartic acid derivative, N-carbamoyl-L-amino acid, N-carbamoylaspartic acid (CHEBI:15859)
Affected organisms
Not Available

Chemical Identifiers

UNII
R2521024DK
CAS number
13184-27-5
InChI Key
HLKXYZVTANABHZ-REOHCLBHSA-N
InChI
InChI=1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)/t2-/m0/s1
IUPAC Name
(2S)-2-(carbamoylamino)butanedioic acid
SMILES
NC(=O)N[C@@H](CC(O)=O)C(O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0000828
KEGG Compound
C00438
PubChem Compound
93072
PubChem Substance
46508886
ChemSpider
84022
ChEBI
15859
ZINC
ZINC000000895230
PDBe Ligand
NCD
Wikipedia
Carbamoyl_aspartic_acid
PDB Entries
1j79 / 1r0c / 1xge / 2z24 / 2z25 / 2z26 / 2z27 / 2z28 / 2z29 / 2z2a
show 19 more

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility21.3 mg/mLALOGPS
logP-1.1ALOGPS
logP-1.7Chemaxon
logS-0.92ALOGPS
pKa (Strongest Acidic)3.33Chemaxon
pKa (Strongest Basic)-2.6Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area129.72 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity34.65 m3·mol-1Chemaxon
Polarizability14.72 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.889
Blood Brain Barrier+0.7569
Caco-2 permeable-0.8346
P-glycoprotein substrateNon-substrate0.7079
P-glycoprotein inhibitor INon-inhibitor0.971
P-glycoprotein inhibitor IINon-inhibitor0.993
Renal organic cation transporterNon-inhibitor0.9717
CYP450 2C9 substrateNon-substrate0.7191
CYP450 2D6 substrateNon-substrate0.8211
CYP450 3A4 substrateNon-substrate0.7788
CYP450 1A2 substrateNon-inhibitor0.9464
CYP450 2C9 inhibitorNon-inhibitor0.9405
CYP450 2D6 inhibitorNon-inhibitor0.9476
CYP450 2C19 inhibitorNon-inhibitor0.9543
CYP450 3A4 inhibitorNon-inhibitor0.8822
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9936
Ames testNon AMES toxic0.8323
CarcinogenicityNon-carcinogens0.9212
BiodegradationReady biodegradable0.8633
Rat acute toxicity1.4895 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9849
hERG inhibition (predictor II)Non-inhibitor0.9794
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (4 TMS)GC-MSsplash10-0f89-3940000000-f6b458a8d8c1bb66550a
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-03di-1910000000-8a8dd39c35aa7c99f81a
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0016-9600000000-c3f9041273a7b07c96ad
GC-MS Spectrum - EI-BGC-MSsplash10-03di-0920000000-cdbae9a5c80fb0023f8e
GC-MS Spectrum - GC-MSGC-MSsplash10-0f89-3940000000-f6b458a8d8c1bb66550a
GC-MS Spectrum - GC-MSGC-MSsplash10-03di-1910000000-8a8dd39c35aa7c99f81a
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-001i-2900000000-8579bc85efea27463b1a
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-00di-9000000000-bfd715a5dec069d32aea
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-00di-9000000000-17769f0943f627a57c64
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-0059-0900000000-d1e136c596eda61fdad6
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-001i-1900000000-d9c4b6edb79ec7db500c
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-000i-9500000000-8a0f02bbd32fdd0af067
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-000i-9100000000-c1e7be64cc9ef25c1291
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-0006-9000000000-d90115a5ff29ff776135
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0059-0900000000-d1e136c596eda61fdad6
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-1900000000-d9c4b6edb79ec7db500c
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-9500000000-ec02387ba0107a9f05cb
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-9100000000-c1e7be64cc9ef25c1291
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-d90115a5ff29ff776135
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-05o0-1900000000-95fcf4ad45ab8d63319a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-9400000000-de503873d712444080d4
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kr-9600000000-c9ec2eb8bdab0e171eb1
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-9000000000-ccc8d380e1001bc7249a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0079-9000000000-af2060d26bad6e5308ca
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-d149930ba09bca62dabd
1H NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-139.1970934
predicted
DarkChem Lite v0.1.0
[M-H]-138.9853934
predicted
DarkChem Lite v0.1.0
[M-H]-129.0905
predicted
DeepCCS 1.0 (2019)
[M+H]+140.2025934
predicted
DarkChem Lite v0.1.0
[M+H]+140.1739934
predicted
DarkChem Lite v0.1.0
[M+H]+131.89668
predicted
DeepCCS 1.0 (2019)
[M+Na]+139.5616934
predicted
DarkChem Lite v0.1.0
[M+Na]+139.8122934
predicted
DarkChem Lite v0.1.0
[M+Na]+140.93079
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
pyrC
Uniprot ID
P05020
Uniprot Name
Dihydroorotase
Molecular Weight
38827.045 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 09, 2021 08:40